Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Molecular Targeted Therapy Market From 2025 to 2029?

The size of the molecular targeted therapy market has witnessed significant growth recently. It is projected to expand from $65.78 billion in 2024 to $71.64 billion in 2025, with a compound annual growth rate (CAGR) of 8.9%. The historical growth can be ascribed to factors such as an upsurge in chronic diseases, a higher demand for tailored medicine, an increasing usage of biomarkers for drug formulation, a rising embrace of monoclonal antibodies, and increased authorizations for oncology treatments.

Strong expansion is anticipated in the molecular targeted therapy market within the coming years. By 2029, it’s predicted to increase to $99.4 billion, with a compound annual growth rate (CAGR) of 8.5%. This projected growth can be linked to several factors such as the escalation in cancer research investment, the rising demand for targeted immunotherapies, broader activities in precision medicine clinical trials, enhanced use of companion diagnostics, and improved healthcare access in developing economies. Key trends during this forecast period are expected to be technological progress in genomics, advancements in drug delivery systems, augmented investment in research and development, improvements in molecular diagnostics, and the adoption of AI technology for therapy discovery.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24609&type=smp

What Elements Are Contributing To Growth In The Molecular Targeted Therapy Market?

The advancement in personalized medicine is projected to augment the molecular targeted therapy market’s expansion in the future. Personalized medicine is an innovative approach to healthcare that tailors treatments and prevention strategies based on the individual’s lifestyle, environmental factors, and genetic makeup. The surge in its popularity stems from the increased accessibility to genetic data, which allows for treatments to be specifically designed for each person’s genome. This results in enhanced efficacy and reduced side effects. Thereby, personalized medicine supports molecular targeted therapy through the thorough analysis of a patient’s tumor for distinct genetic mutations or biomarkers. This process aids in selecting therapies that directly target those abnormalities, ensuring more precision in treatments and minimizing damage to healthy tissues. For instance, the Personalized Medicine Coalition, a healthcare organization from the United States, reported in February 2024 that 16 new tailored treatments for patients with rare diseases were approved by the FDA in 2023, a significant increase from the six treatments approved in 2022. Consequently, the evolution of personalized medicine is propelling the growth of the molecular targeted therapy market.

Which Segments Are Detailed In The Global Molecular Targeted Therapy Market Report?

The molecular targeted therapy market covered in this report is segmented –

1) By Therapy Type: Monoclonal Antibodies, Small Molecule Inhibitors, Gene Therapy, Cell Therapy

2) By Mode Of Administration: Oral, Injectable, Topical, Intravenous

3) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Other Applications

4) By End-User: Hospitals, Clinics, Research Laboratories, Diagnostic Centers

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Small Molecule Inhibitors: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly Adenosine Diphosphate (ADP) Ribose Polymerase (PARP) Inhibitors, Mechanistic Target Of Rapamycin (mTOR) Inhibitors

3) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing

4) By Cell Therapy: Chimeric Antigen Receptor T-Cell Therapy, T-Cell Receptor (TCR) Therapy, Tumor-Infiltrating Lymphocytes (TILs) Therapy, Dendritic Cell Therapy

Which Emerging Trends And Strategic Shifts Are Shaping The Molecular Targeted Therapy Market?

Major players in the molecular targeted therapy market are directing their efforts towards creating innovative products like small molecule inhibitors, aiming to enhance patient results in various cancers and chronic diseases. Small molecule inhibitors are compact compounds capable of easily infiltrating cells and restraining specific proteins contributing to the disease. One example of this is Lumakras (sotorasib), accompanied by Vectibix (panitumumab), presented by Amgen Inc., a US pharmaceutical firm, in January 2025. This combination received the green light from the US Food and Drug Administration (FDA), a US government entity, for use with adult patients suffering from KRAS G12C-mutated metastatic colorectal cancer who had previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy as confirmed by an FDA-certified test. This approval centered around data from the Phase 3 CodeBreaK 300 trial, illustrating that the combination extended progression-free survival twofold compared to the standard of care being studied, marking it as the initial targeted therapy to exhibit such advantages in this chemotherapy-resistant patient group.

Who Are The Key Contributors To Growth In The Molecular Targeted Therapy Market?

Major companies operating in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/molecular-targeted-therapy-global-market-report

Which Region Is Projected To Lead The Molecular Targeted Therapy Market By 2025?

North America was the largest region in the molecular targeted therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular targeted therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24609&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.